Biotechnology Institute Thurgau at Constance University, CH-8280 Kreuzlingen, Switzerland.
J Immunol. 2011 Dec 1;187(11):5548-57. doi: 10.4049/jimmunol.1101064. Epub 2011 Oct 19.
The replacement of the catalytically active proteasome subunits β1, β2, and β5 by the immunoproteasome subunits low molecular mass polypeptide (LMP) 2 (β1i), multicatalytic endopeptidase complex-like-1 (MECL-1) (β2i), and LMP7 (β5i) is required for the production of numerous class I ligands. Hitherto, investigation of the immunoproteasome was confined to the analysis of mice deficient for one or two immunosubunits. In this study, we characterized LMP2(-/-)/MECL-1(-/-) double-deficient mice and used the well-defined LMP7-selective inhibitor ONX 0914 in these mice to generate mice lacking the activity of all immunoproteasome subunits. LMP2(-/-)/MECL-1(-/-) double-deficient mice had strongly reduced numbers of CD8(+) T cells in the spleen. Nevertheless, infection with the lymphocytic choriomeningits virus induced a normal cytotoxic T cell response in these mice, although the T cell response to several class I epitopes was altered. Treatment of LMP2(-/-)/MECL-1(-/-) double-deficient mice with the LMP7-selective inhibitor ONX 0914 elicited a strong CTL response in lymphocytic choriomeningitis virus-infected mice. Thereby, the T(CD8+) response to nucleoprotein 205-212, which is barely detectable in LMP2(-/-)/MECL-1(-/-) double-deficient mice, could be reverted to normal levels by LMP7 inhibition. Additional experiments could demonstrate that the increased CTL response to the nucleoprotein 205-212 in mice lacking functional immunoproteasome is due to an altered class I presentation of this epitope. Taken together, to our knowledge, this is the first study investigating viral infection in mice lacking activity of all three immunoproteasome subunits.
需要通过低分子质量多肽(LMP)2(β1i)、多催化内肽酶复合物样-1(MECL-1)(β2i)和 LMP7(β5i)替代催化活性蛋白酶体亚基β1、β2 和β5,才能产生许多 I 类配体。迄今为止,对免疫蛋白酶体的研究仅限于分析一个或两个免疫亚基缺失的小鼠。在这项研究中,我们对 LMP2(-/-)/MECL-1(-/-)双缺失小鼠进行了特征描述,并在这些小鼠中使用了明确的 LMP7 选择性抑制剂 ONX 0914,以生成缺乏所有免疫蛋白酶体亚基活性的小鼠。LMP2(-/-)/MECL-1(-/-)双缺失小鼠脾脏中 CD8(+)T 细胞数量明显减少。然而,这些小鼠感染淋巴细胞性脉络丛脑膜炎病毒后,仍能产生正常的细胞毒性 T 细胞反应,尽管对一些 I 类表位的 T 细胞反应发生了改变。用 LMP7 选择性抑制剂 ONX 0914 治疗 LMP2(-/-)/MECL-1(-/-)双缺失小鼠可引发感染淋巴细胞性脉络丛脑膜炎病毒的小鼠产生强烈的 CTL 反应。因此,在 LMP2(-/-)/MECL-1(-/-)双缺失小鼠中几乎检测不到的核蛋白 205-212 的 T(CD8+)反应,可以通过 LMP7 抑制恢复到正常水平。进一步的实验表明,缺乏功能性免疫蛋白酶体的小鼠中核蛋白 205-212 的 CTL 反应增加,是由于该表位的 I 类呈递发生改变。总的来说,据我们所知,这是首次研究缺乏所有三种免疫蛋白酶体亚基活性的小鼠中病毒感染的情况。